Black Diamond Therapeutics(BDTX) - 2024 Q3 - Quarterly Results

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update • Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 • Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress • Clinical updates of BDTX-1535 in EGFRm NSCLC and regu ...